What This Report
Will Provide?
This study involved four major
activities in estimating the current size of the NGS-based RNA-sequencing market. Exhaustive secondary
research was carried out to collect information on the market, its peer
markets, and its parent market.
The next step was to validate these findings, assumptions, and sizing with
industry experts across the value chain through primary research. Both top-down
and bottom-up approaches were employed to estimate the complete market size.
After that, market breakdown and data triangulation procedures were used to
estimate the size of segments and subsegments.
Expected Revenue Growth:
The NGS-based RNA-sequencing market size is estimated to grow from USD 1.7 billion
in 2019 to USD 4.2 billion by 2024, at a CAGR of 20.0%.
Major Growth Boosters:
Market growth is driven mainly
by the advantages of RNA-seq over conventional technologies; an increasing
number of RNA-seq grants; rising number of research activities involving
RNA-seq; and rapid growth in precision medicine market.
Applications of NGS-based RNA sequencing:
Based on application, the NGS-based RNA sequencing market is segmented into
expression profiling analysis, small RNA sequencing, De Novo transcriptome
assembly, and variant calling & transcriptome epigenetics. In 2018, the
expression profiling analysis segment accounted for the largest share of the
NGS-based RNA sequencing market. The dominant market position of this segment
is attributed mainly to the increasing prevalence of metabolic disorders,
multiple sclerosis, and other diseases. These factors will continue to propel
the demand for expression profiling analysis to provide specific treatment
options in the market during the forecast period.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102977816
Recent Developments:
In May 2019, BGI (China) and GenomiQa
(Australia) signed a services agreement for whole-genome sequencing on BGI’s
DNBseqTM sequencing technology platform. Under this agreement, genomiQa will
utilize BGI’s ISO15189 accredited laboratory sequencing facilities.
In November 2018, Illumina (US) acquired Pacific Biosciences (US), one of the
leading provider of sequencing systems. This helped Illumina strengthen its
sequencing product portfolio.
In June 2017, Agilent Technologies (US) and Agendia (US) entered into an
agreement to expand their relationship to include the development of Agendia’s
RNA-Seq kit version into Agilent’s current product portfolio.
Key Questions Addressed in The Report:
1. Who are the top 10 players operating in the global NGS-based RNA sequencing market?
2. What are the drivers, restraints, opportunities, and challenges in the NGS-based RNA sequencing
Industry?
3. What are the opportunities for stakeholders and provide details of the
competitive landscape for key players?
4. What will be growth of NGS-based
RNA sequencing in North America, Europe, Asia Pacific, Latin America,
and the Middle East and Africa?
Regional Growth Analysis:
North America accounted for
the largest share of the NGS-based RNA-sequencing market. This can primarily be
attributed to the government support through funds for genomics research, advancements in RNA-Seq
products, growing prevalence of target diseases, growing research on cancer and
inherited rare diseases, and the strong presence of key players such as
Illumina (US), Thermo Fisher (US), and Agilent Technologies (US).
Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=102977816
Key Players:
Illumina
(US), Thermo Fischer Scientific (US) and Oxford Nanopore (UK), Agilent
Technologies, Inc. (US), BGI (China), PerkinElmer Inc. (US), QIAGEN (Germany),
Eurofins Scientific (Luxembourg), F. Hoffmann-La Roche Ltd (Switzerland),
Takara Bio Inc. (Japan), GENEWIZ, Inc. (US), Hamilton Company (US), Macrogen
(South Korea), Zymo Research (US), and Tecan Genomics, Inc. (Switzerland) among
others are the major players operating in the NGS-based RNA-sequencing market.
